beta-alanine has been researched along with Cerebral Ischemia in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 9.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 7.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| "A 70-year-old man with multiple ischemic strokes was diagnosed with cardiac embolism and treated with dabigatran." | 7.80 | Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran. ( Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K, 2014) |
| " Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 7.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 7.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| "Randomized trials suggest superior and safe stroke prevention in patients with atrial fibrillation after anticoagulation with dabigatran (D) at a 150 mg BID as described in the RE-LY prospective randomized open-label trial when compared to warfarin." | 7.78 | Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. ( Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 6.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 5.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 3.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| "A 70-year-old man with multiple ischemic strokes was diagnosed with cardiac embolism and treated with dabigatran." | 3.80 | Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran. ( Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K, 2014) |
| " Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 3.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 3.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| "Randomized trials suggest superior and safe stroke prevention in patients with atrial fibrillation after anticoagulation with dabigatran (D) at a 150 mg BID as described in the RE-LY prospective randomized open-label trial when compared to warfarin." | 3.78 | Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. ( Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| " The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2." | 2.50 | Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? ( Foley, J; Kirchhof, P; Lip, GY, 2014) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 2.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Stroke is a common disease, which is associated with high morbidity and high mortality." | 2.49 | [Anticoagulant therapy in stroke patients]. ( Grove, EL; Husted, SE; Kraglund, KL; Modrau, B, 2013) |
| "Cardioembolic cerebral ischemia can be prevented." | 2.48 | [Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012) |
| "Brain ischemic stroke is among the leading causes of death and long-term disability." | 1.72 | Multi-target action of β-alanine protects cerebellar tissue from ischemic damage. ( Kopach, O; Rusakov, DA; Sylantyev, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kopach, O | 1 |
| Rusakov, DA | 1 |
| Sylantyev, S | 1 |
| Folyovich, A | 1 |
| Varga, V | 1 |
| Béres-Molnár, KA | 1 |
| Vadasdi, K | 1 |
| Bereczki, D | 1 |
| Szapary, L | 1 |
| Fehér, G | 1 |
| Bosnyák, E | 1 |
| Deli, G | 1 |
| Csécsei, P | 1 |
| Müller, P | 1 |
| Topakian, R | 1 |
| Sonnberger, M | 1 |
| Nußbaumer, K | 1 |
| Windpessl, M | 1 |
| Eder, V | 1 |
| Nesser, HJ | 1 |
| Trenkler, J | 1 |
| Haring, HP | 1 |
| Kono, S | 1 |
| Deguchi, K | 1 |
| Omote, Y | 1 |
| Yunoki, T | 1 |
| Yamashita, T | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 1 |
| Abe, K | 1 |
| Finsterer, J | 2 |
| Stöllberger, C | 2 |
| Paul, G | 1 |
| Bastovansky, A | 1 |
| Kate, M | 1 |
| Szkotak, A | 1 |
| Witt, A | 1 |
| Shuaib, A | 1 |
| Butcher, K | 1 |
| Yoshida, K | 1 |
| Kimura, T | 1 |
| Aburakawa, Y | 1 |
| Suzuki, Y | 1 |
| Kuroda, K | 1 |
| Yahara, O | 1 |
| Foley, J | 1 |
| Kirchhof, P | 1 |
| Lip, GY | 1 |
| DeFelipe-Mimbrera, A | 1 |
| Alonso Cánovas, A | 1 |
| Guillán, M | 1 |
| Matute, C | 1 |
| Sainz de la Maza, S | 1 |
| Cruz, A | 1 |
| Vera, R | 1 |
| Masjuan, J | 1 |
| Gil Núñez, A | 2 |
| Takeuchi, S | 1 |
| Wada, K | 1 |
| Nagatani, K | 1 |
| Otani, N | 1 |
| Osada, H | 1 |
| Nawashiro, H | 1 |
| Serebruany, V | 1 |
| Sani, Y | 1 |
| Lynch, D | 1 |
| Schevchuck, A | 1 |
| Svetlov, S | 1 |
| Fong, A | 1 |
| Thevathasan, L | 1 |
| Hanley, D | 1 |
| Diener, HC | 1 |
| Eikelboom, J | 2 |
| Granger, CB | 1 |
| Hacke, W | 1 |
| Healey, JS | 1 |
| Douketis, J | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Yang, S | 1 |
| Themeles, E | 1 |
| Heidbuchel, H | 1 |
| Heidbuchle, H | 1 |
| Avezum, A | 1 |
| Reilly, P | 1 |
| Connolly, SJ | 1 |
| Yusuf, S | 1 |
| Ezekowitz, M | 1 |
| Rakusan, S | 1 |
| Wimpissinger, FT | 1 |
| Shevelev, VI | 1 |
| Kanorsky, SG | 1 |
| Kraglund, KL | 1 |
| Husted, SE | 1 |
| Modrau, B | 1 |
| Grove, EL | 1 |
| de Gea-García, JH | 1 |
| Alvarez, M | 1 |
| Ruiz-Villa, G | 1 |
| Jiménez-Parra, JD | 1 |
| Re, G | 1 |
| Toni, D | 1 |
| Allen, NJ | 1 |
| Rossi, DJ | 1 |
| Attwell, D | 1 |
| Saransaari, P | 1 |
| Oja, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027] | 1,166 participants (Actual) | Observational | 2013-06-30 | Completed | |||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
4 reviews available for beta-alanine and Cerebral Ischemia
| Article | Year |
|---|---|
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2014 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl | 2012 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral He | 2013 |
1 trial available for beta-alanine and Cerebral Ischemia
18 other studies available for beta-alanine and Cerebral Ischemia
| Article | Year |
|---|---|
Multi-target action of β-alanine protects cerebellar tissue from ischemic damage.
Topics: beta-Alanine; Brain; Brain Injuries; Brain Ischemia; Humans; Neuroprotective Agents; Stroke | 2022 |
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, An | 2014 |
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Isc | 2013 |
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coa | 2014 |
Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Heparin, Low-Molecula | 2014 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhag | 2014 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2010 |
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Human | 2012 |
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Topics: Aged; Automation; Benzimidazoles; beta-Alanine; Biomarkers; Brain Ischemia; Calibration; Dabigatran; | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrha | 2012 |
Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombins; Atrial Fibrillati | 2012 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Thrombolysis in ischemic stroke patients on treatment with Dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Humans; Stroke; Thrombolyti | 2013 |
Sequential release of GABA by exocytosis and reversed uptake leads to neuronal swelling in simulated ischemia of hippocampal slices.
Topics: Action Potentials; Animals; beta-Alanine; Brain Ischemia; Calcium; Carrier Proteins; Cell Size; Exci | 2004 |
Characteristics of ischemia-induced taurine release in the developing mouse hippocampus.
Topics: Animals; beta-Alanine; Brain Ischemia; Carrier Proteins; Female; Hippocampus; In Vitro Techniques; K | 1999 |